Pharmacokinetics of Selective Estrogen Receptor Modulators

被引：0
作者：
Karla C. Morello
Gregory T. Wurz
Michael W. DeGregorio
机构：
[1] University of California,Department of Internal Medicine, Division of Hematology/Oncology
[2] Cancer Center,undefined
来源：
Clinical Pharmacokinetics | 2003年 / 42卷
关键词：
Estrogen Receptor; Warfarin; Tamoxifen; Raloxifene; Letrozole;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Selective estrogen receptor modulators (SERMs) are a class of compounds used to treat and prevent breast cancer and osteoporosis. SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene. These compounds are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge. New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a derivative of toremifene, and arzoxifene, a compound very similar in structure to raloxifene.
引用
收藏
页码：361 / 372
页数：11
相关论文
共 195 条
[51]  
Ettinger B.(1996)The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modeling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions Carcinogenesis 17 1357-60
[52]  
Black D.M.(1994)Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes Biochem Pharmacol 47 1883-95
[53]  
Mitlak B.H.(1984)Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes Biochem Pharmacol 33 115-23
[54]  
Walsh B.W.(1980)Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers Cancer Treat Rep 64 761-4
[55]  
Kuller L.H.(1999)Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins Drug Metab Dispos 27 681-8
[56]  
Wild R.A.(1982)Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res 42 317-23
[57]  
Scott J.A.(1990)Biochemical and pharmacological effects of toremifene metabolites Cancer Chemother Pharmacol 27 8-12
[58]  
Camara C.C.(1992)Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer Cancer Chemother Pharmacol 30 174-8
[59]  
Early J.E.(1997)Tamoxifen metabolic patterns within a glioma patient population treated with highdose tamoxifen Br J Clin Pharmacol 43 189-93
[60]  
DeGregorio M.W.(1984)The pharmacology and clinical uses of tamoxifen Pharmacol Ther 25 127-205
12345678910